BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kwun J, Page E, Hong JJ, Gibby A, Yoon J, Farris AB, Villinger F, Knechtle S. Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. Am J Transplant 2015;15:815-22. [PMID: 25675879 DOI: 10.1111/ajt.13045] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Yamamoto T, Iwasaki K, Murotani K, Takeda A, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Watarai Y, Morozumi K, Uchida K, Kobayashi T. Peripheral blood immune response-related gene analysis for evaluating the potential risk of chronic antibody-mediated rejection. Hum Immunol 2018;79:432-8. [PMID: 29614336 DOI: 10.1016/j.humimm.2018.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Shi J, Xu X, Luo F, Shi Q, He X, Xia Y. Differences in Tfh Cell Response Between the Graft and Spleen With Chronic Allograft Nephropathy. Cell Transplant 2017;26:95-102. [PMID: 27524795 DOI: 10.3727/096368916X692816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, Watson CJE, O'Sullivan AM, Chadwick JA, Foster KE, Jones RB, Devey LR, Richards A, Erwig LP, Savage CO, Smith KGC, Henderson RB, Clatworthy MR. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet 2018;391:2619-30. [PMID: 29910042 DOI: 10.1016/S0140-6736(18)30984-X] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 10.8] [Reference Citation Analysis]
4 Agarwal D, Luning Prak ET, Bharani T, Everly M, Migone TS, Cancro M, Allman D, Choe I, Kearns JD, Trofe-Clark J, Naji A, Kamoun M. BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization. Transpl Immunol 2021;69:101465. [PMID: 34506905 DOI: 10.1016/j.trim.2021.101465] [Reference Citation Analysis]
5 Wilson NA, Bath NM, Verhoven BM, Ding X, Boldt BA, Sukhwal A, Zhong W, Panzer SE, Redfield RR 3rd. APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice. Transplantation 2019;103:1372-84. [PMID: 30830041 DOI: 10.1097/TP.0000000000002686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Badell IR, Ford ML. T follicular helper cells in the generation of alloantibody and graft rejection. Curr Opin Organ Transplant 2016;21:1-6. [PMID: 26727455 DOI: 10.1097/MOT.0000000000000260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
7 Rossi AP, Alloway RR, Hildeman D, Woodle ES. Plasma cell biology: Foundations for targeted therapeutic development in transplantation. Immunol Rev 2021;303:168-86. [PMID: 34254320 DOI: 10.1111/imr.13011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fitch Z, Schmitz R, Kwun J, Hering B, Madsen J, Knechtle SJ. Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation. Transplant Rev (Orlando) 2019;33:115-29. [PMID: 31027947 DOI: 10.1016/j.trre.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Mujtaba MA, Komocsar WJ, Nantz E, Samaniego MD, Henson SL, Hague JA, Lobashevsky AL, Higgins NG, Czader M, Book BK, Anderson MD, Pescovitz MD, Taber TE. Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. Am J Transplant 2016;16:1266-75. [PMID: 26780484 DOI: 10.1111/ajt.13557] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
10 Wu S, Su X, Ye Q, Wei Y, Gao Y, Huang M, Chen Y, Wang J, Zhang Q, Fu Q, Li J, Wu C, Huang H, Xu B, Zhang H, Liu L, Wang C. Serum Soluble B Cell-Activating Factor Is a Non-Invasive Biomarker of Antibody-Mediated Rejection in Kidney Allograft With Satisfactory Risk Stratification Performance But Negligible Diagnostic Value. Front Immunol 2022;13:869444. [DOI: 10.3389/fimmu.2022.869444] [Reference Citation Analysis]
11 Kwun J, Burghuber C, Manook M, Iwakoshi N, Gibby A, Hong JJ, Knechtle S. Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. J Am Soc Nephrol 2017;28:1991-6. [PMID: 28232617 DOI: 10.1681/ASN.2016070727] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
12 Ezekian B, Schroder PM, Mulvihill MS, Barbas A, Collins B, Freischlag K, Yoon J, Yi JS, Smith F, Olaso D, Saccoccio FM, Permar S, Farris AB, Kwun J, Knechtle SJ. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. J Am Soc Nephrol 2019;30:2399-411. [PMID: 31658991 DOI: 10.1681/ASN.2019030304] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
13 Afzali S, Salehi S, Shahi A, Amirzargar A. B cell modulation strategies in the improvement of transplantation outcomes. Mol Immunol 2020;125:140-50. [PMID: 32682148 DOI: 10.1016/j.molimm.2020.06.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chu Z, Zou W, Xu Y, Sun Q, Zhao Y. The regulatory roles of B cell subsets in transplantation. Expert Review of Clinical Immunology 2018;14:115-25. [DOI: 10.1080/1744666x.2018.1426461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Degner KR, Wilson NA, Reese SR, Parajuli S, Aziz F, Garg N, Mohamed M, Singh T, Mandelbrot DA, Panzer SE, Redfield RR, Van Hyfte K, Zhong W, Hidalgo LG, Djamali A. Short-Term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection. Kidney360 2020;1:389-98. [DOI: 10.34067/kid.0001082019] [Reference Citation Analysis]
16 Karahan GE, Claas FH, Heidt S. B Cell Immunity in Solid Organ Transplantation. Front Immunol 2016;7:686. [PMID: 28119695 DOI: 10.3389/fimmu.2016.00686] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
17 Inaba A, Clatworthy MR. Novel immunotherapeutic strategies to target alloantibody-producing B and plasma cells in transplantation: . Current Opinion in Organ Transplantation 2016;21:419-26. [DOI: 10.1097/mot.0000000000000338] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
18 Hong JJ, Silveira ELDV, Amancha PK, Byrareddy SN, Gumber S, Chang KT, Ansari AA, Villinger F. Early initiation of antiretroviral treatment postSIV infection does not resolve lymphoid tissue activation. AIDS 2017;31:1819-24. [PMID: 28692537 DOI: 10.1097/QAD.0000000000001576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
19 Dijke EI, Platt JL, Blair P, Clatworthy MR, Patel JK, Kfoury AG, Cascalho M. B cells in transplantation. J Heart Lung Transplant 2016;35:704-10. [PMID: 26996930 DOI: 10.1016/j.healun.2016.01.1232] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
20 Knechtle SJ, Shaw JM, Hering BJ, Kraemer K, Madsen JC. Translational impact of NIH-funded nonhuman primate research in transplantation. Sci Transl Med 2019;11:eaau0143. [PMID: 31292263 DOI: 10.1126/scitranslmed.aau0143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
21 Dangi A, Yu S, Lee FT, Burnette M, Knechtle S, Kwun J, Luo X. Donor apoptotic cell-based therapy for effective inhibition of donor-specific memory T and B cells to promote long-term allograft survival in allosensitized recipients. Am J Transplant 2020;20:2728-39. [PMID: 32275799 DOI: 10.1111/ajt.15878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Kwun J, Manook M, Page E, Burghuber C, Hong J, Knechtle SJ. Crosstalk Between T and B Cells in the Germinal Center After Transplantation. Transplantation 2017;101:704-12. [PMID: 27906827 DOI: 10.1097/TP.0000000000001588] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 6.8] [Reference Citation Analysis]
23 Atia A, Moris D, McRae M, Song M, Stempora L, Leopardi F, Williams K, Kwun J, Parker W, Cardones AR, Kirk AD, Cendales LC. Th17 cell inhibition in a costimulation blockade-based regimen for vascularized composite allotransplantation using a nonhuman primate model. Transpl Int 2020;33:1294-301. [PMID: 32277724 DOI: 10.1111/tri.13612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Haririan A. Current status of the evaluation and management of antibody-mediated rejection in kidney transplantation: . Current Opinion in Nephrology and Hypertension 2015;24:576-81. [DOI: 10.1097/mnh.0000000000000167] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Bath NM, Ding X, Wilson NA, Verhoven BM, Boldt BA, Sukhwal A, Reese SR, Panzer SE, Djamali A, Redfield RR 3rd. Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model. PLoS One 2019;14:e0211865. [PMID: 30735519 DOI: 10.1371/journal.pone.0211865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
26 OʼLeary JG, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, Cozzi E. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation 2016;100:39-53. [PMID: 26680372 DOI: 10.1097/TP.0000000000000869] [Cited by in Crossref: 73] [Cited by in F6Publishing: 21] [Article Influence: 12.2] [Reference Citation Analysis]
27 Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. J Clin Invest 2017;127:2492-504. [PMID: 28604384 DOI: 10.1172/JCI90597] [Cited by in Crossref: 83] [Cited by in F6Publishing: 36] [Article Influence: 16.6] [Reference Citation Analysis]
28 Friebus-Kardash J, Wilde B, Keles D, Heinold A, Kribben A, Witzke O, Heinemann FM, Eisenberger U. Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. Transpl Immunol 2018;47:10-7. [PMID: 29277566 DOI: 10.1016/j.trim.2017.12.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
29 Shin HS, Grgic I, Chandraker A. Novel Targets of Immunosuppression in Transplantation. Clin Lab Med 2019;39:157-69. [PMID: 30709504 DOI: 10.1016/j.cll.2018.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ohm B, Jungraithmayr W. B Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications. Front Immunol 2022;13:845867. [DOI: 10.3389/fimmu.2022.845867] [Reference Citation Analysis]
31 Afzali S, Salehi S, Shahi A, Esmaeili M, Farashi Bonab S, Peykari A, Bagherpour F, Ansaripour B, Soleimanian T, Pour-Reza-Gholi F, Amirzargar A. Investigating the Role of BAFF and Its Receptors in Renal Transplant Recipients with Chronic Antibody-Mediated Rejection. J Immunol Res 2021;2021:6654992. [PMID: 33748289 DOI: 10.1155/2021/6654992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Suchanek O, Clatworthy MR. Novel strategies to target the humoral alloimmune response. HLA 2020;96:667-80. [PMID: 33022883 DOI: 10.1111/tan.14092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Olaso D, Manook M, Moris D, Knechtle S, Kwun J. Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient. J Clin Med 2021;10:3656. [PMID: 34441950 DOI: 10.3390/jcm10163656] [Reference Citation Analysis]
34 Leibler C, Thiolat A, Elsner RA, El Karoui K, Samson C, Grimbert P. Costimulatory blockade molecules and B-cell-mediated immune response: current knowledge and perspectives. Kidney Int 2019;95:774-86. [PMID: 30711200 DOI: 10.1016/j.kint.2018.10.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Ilahe A, Budhiraja P, Kaplan B. Polyclonal and monoclonal antibodies in renal transplant: an update. Curr Opin Nephrol Hypertens 2015;24:563-9. [PMID: 26418057 DOI: 10.1097/MNH.0000000000000171] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Oh B, Yoon J, Farris A 3rd, Kirk A, Knechtle S, Kwun J. Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. Am J Transplant 2016;16:2612-23. [PMID: 26990829 DOI: 10.1111/ajt.13789] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
37 Xu H, He X, Xu R. B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome. J Immunol Res 2018;2018:5251801. [PMID: 29977928 DOI: 10.1155/2018/5251801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Agarwal D, Allman D, Naji A. Novel therapeutic opportunities afforded by plasma cell biology in transplantation. Am J Transplant 2020;20:1984-91. [PMID: 32034987 DOI: 10.1111/ajt.15813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Degner KR, Wilson NA, Reese SR, Parajuli S, Aziz F, Garg N, Mohamed M, Singh T, Mandelbrot DA, Panzer SE, Redfield RR, Van Hyfte K, Zhong W, Hidalgo LG, Djamali A. Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection. Kidney360 2020;1:389-98. [PMID: 34476406 DOI: 10.34067/kid.0001082019] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kwun J, Knechtle S. Experimental modeling of desensitization: What have we learned about preventing AMR? Am J Transplant 2020;20 Suppl 4:2-11. [PMID: 32538533 DOI: 10.1111/ajt.15873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]